Table 1 Characteristics of included studies
Characteristics | Studies [n (%)] | Characteristics | Studies [n (%)] |
|---|---|---|---|
Country | Â | Publication Year | Â |
USA | 56(29.9) | 2013 | 8(4.3) |
Germany | 16(8.6) | 2014 | 10(5.3) |
Japan | 14(7.5) | 2015 | 15(8) |
Korea | 13(7) | 2016 | 14(7.5) |
China | 11(5.9) | 2017 | 24(12.8) |
Denmark | 10(5.3) | 2018 | 26(13.9) |
Spain | 9(4.8) | 2019 | 29(15.5) |
Italy | 9(4.8) | 2020 | 31(16.6) |
Other | 49(26.2) | 2021 | 30(16) |
Diseases | Â | Type of Therapies | Â |
Cancer | 32(16.7) | Drug | 106(56.7) |
Diabetes Mellitus | 22(11.5) | Antibody | 26(13.9) |
Arthritis | 15(7.8) | Device | 22(11.8) |
Coronary Disease | 15(7.8) | Surgery | 16(8.6) |
Chronic Hepatitis C | 8(4.2) | Chemotherapy/Radiotherapy | 6(3.2) |
Myocardial Infarction | 8(4.2) | Biologics | 5(2.7) |
Atrial Fibrillation | 7(3.6) | Allograft | 3(1.6) |
Neoplasm | 7(3.6) | Vaccination | 2(1.1) |
Multiple Sclerosis | 6(3.1) | Acupuncture | 1(0.5) |
Hypertension | 5(2.6) | Â | Â |
Psoriasis | 5(2.6) | Â | Â |
Stroke | 3(1.6) | Â | Â |
Diabetic Foot Ulcers | 2(1) | Â | Â |
Heart Failure | 2(1) | Â | Â |
Other | 55(28.6) | Â | Â |
Type of Data Sources | Â | Number of databases | Â |
Multicenter Registry | 116(62) | 1 | 121(64.7) |
Single center registry | 6(3.2) | 2 | 32(17.1) |
EMR/EHR | 34(18.2) | 3 | 13(7) |
Claims | 11(5.9) | 4 | 5(2.7) |
Other | 29(15.5) | ≥ 5 | 16(8.6) |
Journal IF (n = 176) |  | Citations (n = 187) |  |
Median (IQR) | 3.54(2.4,5.55) | Median (IQR) | 12(6,25) |
Range | 0.52–27.97 | Range | 0-548 |